Genevant offers a lipid nanoparticle (LNP) platform that enables clinical development of RNA-based therapeutics. Its proprietary ligand conjugate delivery platform has been designed for RNAi therapeutics targeting the liver. The company intends to develop numerous RNAi-conjugate products in-house targeting a wide range of genetically-defined diseases.